RE:RE:RE:Online WebinarsMartyD I'm curious as 2023 per Alvira was all about bringing awareness of the product to the community as Ventripoint made many references to all the conferences they attended in 2023. I hope you are wrong on 2024 and we see some decent sales traction as another year of a few sales isn't going to break it. The stock will be diluted under that case 1-3 times and it leaves more room for a potential competitor or ge HC to build their own vms (research the ai cardio company GEHC bought recently). Its time for vms to be adopted as $50k isn't a large price tag for a device-software that does all it can and reduces time and cost to a HC system.